The comparative safety of abciximab versus eptifibatide in patients on dialysis undergoing percutaneous coronary intervention: Insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2). [electronic resource]
Producer: 20180322Description: 291-300 p. digitalISSN:- 1540-8183
- Abciximab
- Aged
- Antibodies, Monoclonal -- therapeutic use
- Blue Cross Blue Shield Insurance Plans
- Contraindications, Drug
- Eptifibatide
- Female
- Heparin -- therapeutic use
- Humans
- Immunoglobulin Fab Fragments -- therapeutic use
- Male
- Michigan
- Middle Aged
- Myocardial Infarction -- therapy
- Peptides -- therapeutic use
- Percutaneous Coronary Intervention
- Platelet Aggregation Inhibitors -- therapeutic use
- Platelet Glycoprotein GPIIb-IIIa Complex -- antagonists & inhibitors
- Postoperative Complications -- epidemiology
- Renal Dialysis
- Retrospective Studies
- Treatment Outcome
No physical items for this record
Publication Type: Comparative Study; Journal Article
There are no comments on this title.
Log in to your account to post a comment.